CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
sildenafil citrate +1 moredrug
Likely dose
Sildenafil citrate 25 mg orally three times dailyAI-extracted
Key inclusion· 4
  • ✓Clinical diagnosis of COPD or emphysema
  • ✓Airflow obstruction: FEV1/FVC ratio <70%
  • ✓Reduced FEV1: <80% predicted
  • ✓Stable medication regimen at enrollment
Key exclusion· 7
  • ✕COPD exacerbation or hospitalization within past 3 months
  • ✕Heart disease
  • ✕Contraindication to sildenafil use
  • ✕Unrelated lung disease (comorbid pulmonary conditions)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00104637
NCT00104637Phase 2Completed
CompareCT.gov

A Double-blind, Placebo-controlled, Crossover Study of Sildenafil in Patients With Chronic Obstructive Pulmonary Disease

Kawut, Steven, MD·interventional·Posted Mar 4, 2005·Updated May 21, 2012

In Brief

A Phase 2 clinical trial evaluating sildenafil citrate and Placebo for Pulmonary Disease, Chronic Obstructive and Emphysema. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if sildenafil improves the exercise capacity and lung function of patients with chronic obstructive pulmonary disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive, Emphysema
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 4, 2005
Enrollment StartFeb 1, 2005
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 21.3 years ago

Interventions

sildenafil citratedrug

sildenafil citrate 25 mg by mouth thrice daily (po tid)

Placebodrug

25 mg po tid